Integrating behavioral and pharmacological interventions in treating clients with psychiatric disorders and mental retardation.

Cullinan et al. (2001) wrote a how-to paper for BCBAs who work with clients on psych meds. They used stories from real cases to show when pills help or hurt the behavior plan.

The paper is not a lab study. It is a map for talking with doctors so meds and ABA work together, not against each other.

The big idea: the same pill can speed up learning one day and block it the next. The only way to know is to track behavior every day and share the graphs with the prescriber.

Case stories showed that dose changes often caused new problem behavior. Quick data sharing let the team fix the dose before the behavior plan had to be rebuilt.

Cox et al. (2022) later tested the idea with clinic files from teens with IDD. They found that changing the behavior plan cut problem behavior more than changing the pill, backing up the 2001 call to put ABA in the driver’s seat.

Bird et al. (2022) gave a ready-made fix: an Interdisciplinary Review Team—BCBA, nurse, doctor, parents—met monthly and safely removed meds from kids with ASD. Their team huddle is the real-world version of the 2001 coordination plea.

Friman (2014) pushed the field further by asking for math models that predict exactly how a med tweaks the contingency. The 2001 paper said ‘talk to each other’; Friman (2014) said ‘build equations so you can predict.’

You do not need to wait for perfect models. Start the conversation now. Add a med review slot to every treatment-plan meeting. Bring one week of behavior data and ask, ‘Is this dose still helping our plan?’ That single question can prevent months of wasted sessions.